Talimogene Laherparepvec: Side Effects, Uses & Monitoring

Facts extracted from current FDA product labeling for Talimogene Laherparepvec. Educational only — not medical advice.

Labeled uses

IMLYGIC is a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery. Limitations of use : IMLYGIC has not been shown to improve overall survival or have an effect on visceral metastases.

Source: FDA labeling via NIH DailyMed (set 64ffb680…). Not affiliated with FDA or NIH.

Medical disclaimer: Always consult a qualified healthcare professional about any medication.

Ratings summarize government-reported measures — they don't capture your personal needs. Visit the facility, ask about staffing and services, and use CMS checklists. This profile is informational only and is not a recommendation.